Welcome to our dedicated page for Nutriband news (Ticker: NTRBW), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
Company Overview
Nutriband Inc. is a specialized pharmaceutical company based in Oviedo, Florida, that focuses on cutting-edge transdermal and topical technologies. The company has built its expertise around developing a portfolio of innovative transdermal products, with a primary focus on its abuse-deterrent technology known as AVERSA. This proprietary technology integrates aversive agents into transdermal patches to prevent abuse, misuse, diversion, and accidental exposure of drugs with high abuse potential, such as opioids and stimulants.
Core Business and Product Portfolio
The centerpiece of Nutriband’s portfolio is its lead product under development, an abuse-deterrent fentanyl patch that incorporates AVERSA technology. By employing a unique coating mechanism that leverages taste aversion, the patch is designed to deter the oral abuse of potent medications while ensuring that patients in need retain access to essential pain management solutions. The company also extends its technological expertise to other product categories, including transdermal consumer goods and a mosquito repellent patch, evidencing a diverse application of its platform.
Innovative Technology and Intellectual Property
Nutriband’s AVERSA technology is at the forefront of addressing the challenges posed by the global opioid crisis. The unique methodology of incorporating aversive agents, such as the well-known bitter compound Bitrex®, into patches is underpinned by a robust international intellectual property portfolio, with patents granted in 46 countries. This extensive protection not only reinforces the company’s market position but also demonstrates its commitment to innovation and drug safety.
Strategic Partnerships and Operational Excellence
The company has established strategic alliances with prominent partners in the pharmaceutical and manufacturing sectors. Its collaboration with Kindeva Drug Delivery enables Nutriband to integrate its abuse-deterrent technology into FDA-approved transdermal systems, thereby optimizing the manufacturing and regulatory pathway for its lead products. Additionally, Nutriband’s subsidiary, Pocono Pharma, bolsters its contract manufacturing services, distributing a variety of products to major retail channels across the United States.
Market Position and Business Model
Nutriband positions itself within a highly specialized niche of the pharmaceutical industry, focusing on transdermal applications that enhance drug safety while combating abuse potential. The company generates revenue primarily through the sale of its consumer transdermal products and contract manufacturing services, coupled with the anticipated benefits from its innovative abuse-deterrent technology. By streamlining regulatory processes and leveraging a single Phase 1 trial for its abuse-deterrent product, Nutriband demonstrates a pragmatic approach to market entry while ensuring rigorous compliance with safety standards.
Commitment to Safety and Market Impact
At its core, Nutriband is dedicated to addressing critical public health challenges by improving the safety profile of transdermal pharmaceutical products. The incorporation of AVERSA technology into products such as a fentanyl patch not only aims to reduce the risk of misuse and diversion but also helps prevent accidental exposure, which is particularly important in vulnerable populations. This dual focus on efficacy and safety underscores the company’s role in mitigating the impact of drug abuse while supporting the legitimate medical needs of patients.
Conclusion
Overall, Nutriband Inc. represents a blend of technological innovation, strategic operational partnerships, and a deep commitment to enhancing drug safety. Its comprehensive approach in leveraging abuse-deterrent transdermal technology sets it apart in a competitive industry. Investors and analysts looking for insights into innovative pharmaceutical strategies will find Nutriband’s focus on sustainable, safety-driven solutions to be of considerable significance.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has announced its integration with Webull's Corporate Communications Service Platform, enhancing its investor relations and corporate communications capabilities. This partnership aims to boost Nutriband's visibility and engagement with current and potential investors by providing direct notifications of corporate news, earnings, and investor presentations. CEO Gareth Sheridan emphasized the importance of this platform for delivering timely and accurate information to shareholders. Nutriband is focused on developing transdermal pharmaceutical products, including an abuse deterrent fentanyl patch using its advanced AVERSA™ technology.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced on March 2, 2023, that Alan Smith, Ph.D., COO and President of its subsidiary, 4P Therapeutics, was appointed to the FDA's Center for Research on Complex Generics Stakeholder Expert Committee on Adhesion Testing for transdermal delivery systems. This committee aims to enhance collaboration between the FDA and industry for developing safe generic products. Dr. Smith brings over 25 years of expertise in transdermal drug delivery systems. Nutriband focuses on developing innovative transdermal products, including its abuse-deterrent fentanyl patch, using proprietary AVERSA™ technology.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced it has completed the necessary steps to submit its application to Ecuador's Health Register, allowing for the distribution of medical devices and cosmetic products in South America. This move opens access to the Andean Community, which includes four countries: Colombia, Ecuador, Peru, and Bolivia, with a combined population exceeding 114 million. Nutriband is focused on developing transdermal pharmaceutical products, including its lead product, an abuse-deterrent fentanyl patch utilizing AVERSA™ technology. The company is navigating various risks associated with product development and regulatory approvals.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) is showcasing its innovations at the 2023 Transdermal and Microneedle Conference in London on January 23-24, 2023. CEO Gareth Sheridan will present on January 24 at 11:00 a.m. GMT, focusing on enhancing transdermal technologies to minimize liability regarding abusable medications. COO Dr. Alan Smith will join a panel discussion at 11:40 a.m. GMT about microneedle applications in drug delivery. The conference will also feature industry leaders including Merck and GSK. Nutriband's AVERSA technology aims to prevent drug abuse, emphasizing safety in chronic pain treatments.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has dual-listed on Upstream, a platform for digital securities and NFTs, enhancing its accessibility to global investors. The listing became effective on January 5, 2023, allowing trades in real-time through Upstream's transparent order book. A commemorative NFT for this listing is also available. CEO Gareth Sheridan emphasized the listing's value for shareholders and the company’s mission to reach a modern investor base. However, U.S. investors are only allowed to liquidate existing holdings on Upstream.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has announced its dual listing on Upstream, commencing January 5, 2023. This move positions Nutriband as the first company to utilize Upstream's platform, allowing global investors to trade using various payment methods, including USDC digital currency. The dual listing aims to enhance liquidity, price discovery, and accessibility for U.S. investors. Nutriband's primary focus is developing transdermal pharmaceutical products, notably an abuse deterrent fentanyl patch utilizing AVERSA™ technology, which is crucial for preventing drug abuse.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has commenced production of its AI Tape brand, with an anticipated launch in Q1 2023. The new product aims to enhance traditional Kinesiology Tape by incorporating therapeutic ingredients in a proprietary adhesive mix. Production is taking place at the company's facility in North Carolina. Nutriband focuses on transdermal pharmaceutical products, developing an abuse deterrent fentanyl patch using its AVERSA™ technology. This aims to prevent drug misuse and accidental exposure.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has announced its approval for a dual listing on Upstream, with trading set to begin on January 5, 2023. This move aims to enhance liquidity and broaden its investor base by allowing trading in digital currencies like USDC and traditional payment methods. Participants will also receive a commemorative NFT on listing day. CEO Gareth Sheridan highlighted that this listing will facilitate reaching international markets and bolster shareholder value as the company develops its AVERSA™ technology for transdermal products.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) will feature on The RedChip Money Report on Bloomberg TV, airing December 17, 2022, at 7 p.m. ET. The interview will showcase Nutriband's transdermal technology and its applications, led by Chief Scientific Officer Dr. Jeff Patrick. This technology includes the development of an abuse deterrent fentanyl patch utilizing AVERSA™ technology. The segment will be accessible to an estimated 73 million U.S. homes. For full access to the interview, visit here.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) reported a record revenue of $620,000 for Q3 2022, marking a 118% increase from Q3 2021. Year-to-date revenue reached $1,552,074, a 67% year-over-year growth. The company continues to expand its AVERSA™ intellectual property portfolio with patents granted in 44 countries. Net loss decreased to $1.07 million from $1.57 million in the prior year. CEO Gareth Sheridan highlighted potential peak sales for AVERSA Fentanyl could range between $80 million to $200 million.
FAQ
What is the current stock price of Nutriband (NTRBW)?
What is Nutriband Inc.'s core business?
How does AVERSA technology work?
What sets Nutriband apart from its competitors?
In which markets is Nutriband active?
How does the company generate revenue?
What is the significance of the company’s intellectual property portfolio?
How does Nutriband ensure the safety of its transdermal products?
What role do strategic partnerships play in Nutriband’s operations?
